Holder | Position | Change | Date | |
---|---|---|---|---|
No active short positions |
Holder | Position | Change (%) | Date | |
---|---|---|---|---|
WorldQuant LLC | 0.47% | 12-Mar-2018 | View History | |
WorldQuant LLC | 0.5% | 05-Mar-2018 | View History | |
WorldQuant LLC | 0.49% | 22-Feb-2018 | View History | |
WorldQuant LLC | 0.5% | 21-Feb-2018 | View History | |
WorldQuant LLC | 0.49% | 19-Feb-2018 | View History | |
WorldQuant LLC | 0.51% | 14-Feb-2018 | View History | |
Darwin Strategic Limited | 0% | 14-Oct-2013 | View History | |
Darwin Strategic Limited | 0.91% | 08-Oct-2013 | View History | |
Darwin Strategic Limited | 0.87% | 03-Oct-2013 | View History | |
Darwin Strategic Limited | 0.94% | 01-Oct-2013 | View History | |
Darwin Strategic Limited | 1.04% | 27-Sep-2013 | View History | |
Darwin Strategic Limited | 0.76% | 25-Sep-2013 | View History | |
Darwin Strategic Limited | 0.6% | 24-Sep-2013 | View History | |
Darwin Strategic Limited | 0.54% | 23-Sep-2013 | View History |
ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France.
ImmuPharma listed on AIM under the ticker IMM.
IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.
IMM share price listed in London at 1,190p in 2000.